Immunotherapy combo shows promise in advanced lung cancer trial
NCT ID NCT03694236
First seen May 16, 2026 · Last updated May 16, 2026
Summary
This study tests adding the immunotherapy drug durvalumab to standard chemotherapy and radiation before surgery for people with stage III non-small cell lung cancer that can be removed. The goal is to see if this combination is safe and can improve outcomes like tumor shrinkage and survival. About 39 adults will take part, and researchers will also study tissue samples to understand how the immune system responds.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POTENTIALLY RESECTABLE STAGE II/IIIA NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Severance Hospital
RECRUITINGSeoul, Seoul, 03722, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.